BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Proxima Therapeutics Enters Into Agreement To Be Acquired By Cytyc Corporation (CYTC); $160 Million


10/19/2005 5:12:40 PM

ALPHARETTA, Ga.--(BUSINESS WIRE)--Feb. 9, 2005--Proxima Therapeutics, Inc., a privately-held developer and marketer of internally-delivered, site-specific cancer treatment systems, today announced that it has entered into a definitive agreement to be acquired by Cytyc Corporation (Nasdaq: CYTC - News), a leading women's health company. Under the terms of the agreement, Proxima will be acquired by Cytyc in an all cash transaction for a purchase price of $160 million plus a two-year earnout based on incremental sales growth in 2005 and 2006. Proxima's leading product is the MammoSite® Radiation Therapy System (RTS) for the treatment of breast cancer. MammoSite enables eligible patients who have undergone a lumpectomy to receive partial breast irradiation (PBI), the practice of delivering radiation only to the area where tumors are most likely to recur, while minimizing exposure to healthy tissue. The MammoSite device is a balloon catheter that delivers a prescribed dose of radiation from inside the cavity created by the removal of the breast tumor in just five days.

Since its clearance by the U.S. Food and Drug Administration (FDA) in 2002, MammoSite has been used to treat more than 7,000 breast cancer patients. In addition to MammoSite, Proxima markets the GliaSite RTS, a site-specific radiation treatment for brain tumors.

"MammoSite is already a market leader in partial breast irradiation, and by combining forces with the infrastructure and resources of Cytyc's rapidly growing women's health franchise we expect that this important therapy will now become even more accessible to breast cancer patients," said Timothy Patrick, CEO of Proxima Therapeutics. "This would not have been possible without the talents and contributions of the many employees at Proxima Therapeutics whose efforts have helped bring important new treatment options to the patients who need them."

About Proxima Therapeutics, Inc.

Based in Alpharetta, Ga., Proxima Therapeutics, Inc. is a privately held medical device company established in 1995 to develop site-specific cancer treatment systems for malignant tumors. Marketed products include MammoSite RTS for breast cancer and GliaSite RTS for brain cancer. Additional information is available on the company's Web site at www.proximatherapeutics.com. Physicians and patients may call 1-866-PROXIMA (1-866-776-9462) for more information.

Contact:

Schwartz Communications Jim Weinrebe/Wendy Williams, 781-684-0770 proxima@schwartz-pr.com or

Proxima Therapeutics, Inc. Tim Patrick, 770-753-4848

Source: Proxima Therapeutics, Inc.



Read at Dow Jones
Read at BioSpace.com
Read at LocalTechWire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES